Empowered Funds LLC Makes New Investment in Inspire Medical Systems, Inc. $INSP

Empowered Funds LLC purchased a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 34,876 shares of the company’s stock, valued at approximately $1,799,000. Empowered Funds LLC owned about 0.12% of Inspire Medical Systems as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in INSP. CWM LLC boosted its position in shares of Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after buying an additional 242 shares during the last quarter. Havemeyer Place LP bought a new stake in Inspire Medical Systems during the fourth quarter worth $39,000. V Square Quantitative Management LLC purchased a new stake in Inspire Medical Systems in the 4th quarter valued at $40,000. Smartleaf Asset Management LLC raised its position in Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after buying an additional 205 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on INSP shares. Robert W. Baird upped their target price on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a research note on Tuesday. Truist Financial reissued a “hold” rating and set a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday. Summit Redstone set a $39.00 price target on shares of Inspire Medical Systems in a report on Friday, May 22nd. Mizuho upped their price objective on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $68.00.

Inspire Medical Systems Stock Down 2.0%

Inspire Medical Systems stock opened at $58.91 on Friday. The firm has a 50 day moving average price of $47.26 and a 200-day moving average price of $54.48. Inspire Medical Systems, Inc. has a twelve month low of $38.91 and a twelve month high of $147.03. The company has a market capitalization of $1.70 billion, a P/E ratio of 12.75, a P/E/G ratio of 4.55 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. During the same quarter in the previous year, the firm posted $0.45 EPS. Inspire Medical Systems’s revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities analysts expect that Inspire Medical Systems, Inc. will post 1.24 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.